# Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

> **NCT00660192** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 25 (actual)

## Conditions studied

- Refractory Migraine

## Interventions

- **DRUG:** Botox
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00660192
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-07
- **Final completion:** 2015-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660192, "Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00660192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*